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Abstract 
Background:Trigeminal neuropathic pain (TNP) is an often debilitating facial pain syndrome for which 
there is no known cure or effective treatment. It differs from its more commonly known counterpart, 
trigeminal neuralgia (TN), in that it is constant and does not have an anatomical etiology which would 
allow for surgical correction. TNP is frequently refractory to pharmacologic therapy using high dose 
antiepileptics. Previous attempts to use nerve stimulation as a treatment method involved invasive 
surgical techniques and frequent electrode migration. 
Methods: Exhaustive search of available medical literature was conducted using Clinical Key, MEDLINE-
Ovid and Web of Science and the following search terms: trigeminal neuropathic pain, neuromodulation 
and stimulation. Articles were assessed for quality using GRADE criteria. 
Results: Two case series studies fit all eligibility criteria. Each utilized a temporary electrode placed for a 
trial period to assess efficacy and determine candidacy for permanent implantation. One study found that 
in those with a positive trial, 96.3% at 6 months and 46.7% of patients at 24 months experienced pain 
reduction from baseline. Another study found that 62.5% of patients with a positive trial experienced pain 
reduction at 6 months, with 37.5% still experiencing pain reduction at 12 months. 
Conclusion: Stimulation of the Gasserian ganglion (GG) may be an effective treatment for long-term pain 
reduction in TNP; however, current studies are of very low quality due to small cohort size and lack of an 
RCT. 
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Abstract   
 
Background: Trigeminal neuropathic pain (TNP) is an often 
debilitating facial pain syndrome for which there is no known cure or 
effective treatment. It differs from its more commonly known 
counterpart, trigeminal neuralgia (TN), in that it is constant and does 
not have an anatomical etiology which would allow for surgical 
correction. TNP is frequently refractory to pharmacologic therapy using 
high dose antiepileptics. Previous attempts to use nerve stimulation as 
a treatment method involved invasive surgical techniques and frequent 
electrode migration.  
 
Methods:  Exhaustive search of available medical literature was 
conducted using Clinical Key, MEDLINE-Ovid and Web of Science and 
the following search terms: trigeminal neuropathic pain, 
neuromodulation and stimulation. Articles were assessed for quality 
using GRADE criteria.  
 
Results:  Two case series studies fit all eligibility criteria. Each utilized 
a temporary electrode placed for a trial period to assess efficacy and 
determine candidacy for permanent implantation. One study found 
that in those with a positive trial, 96.3% at 6 months and 46.7% of 
patients at 24 months experienced pain reduction from baseline. 
Another study found that 62.5% of patients with a positive trial 
experienced pain reduction at 6 months, with 37.5% still experiencing 
pain reduction at 12 months.  
 
Conclusion:  Stimulation of the Gasserian ganglion (GG) may be an 
effective treatment for long-term pain reduction in TNP; however, 
current studies are of very low quality due to small cohort size and 
lack of an RCT.   
 
Keywords:  Trigeminal neuropathic pain, Gasserian ganglion, 
trigeminal neuropathy, stimulation, neuromodulation  
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Trigeminal Nerve Stimulation for Trigeminal 
Neuropathic Pain Refractory to Medical 
Management 
 
BACKGROUND 
Trigeminal neuropathic pain (TNP) is a chronic, often debilitating, 
facial pain syndrome for which there is no adequate treatment. It’s 
quality and severity vary amongst patients, as does its etiology--most 
commonly direct injury to the trigeminal nerve leading to neural 
damage via trauma, dental procedures, or zoster infections. TNP can 
also be idiopathic.1 TNP can affect any combination of the three 
branches of the fifth cranial nerve. TNP, and its more popular 
counterpart, trigeminal neuralgia (TN), are believed to be “one of the 
most severe pain types known to humanity,” and were previously 
referred to as ‘suicide disease’ given the large burden of people who 
took their own lives as a result of their intractable pain.2  
Both TNP and TN share similar etiologies but differ in their 
diagnostic criteria and treatment approach. Although TN can be 
subclassified by etiology, “classic” TN requires that an anatomical 
cause--such as neurovascular compression or a plaque (ie multiple 
sclerosis) is seen on MRI.1,3 The presence of this anatomical 
relationship allows for targeted treatment--microvascular 
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decompression of the affected area. Additionally, classic TN is 
characterized by brief, paroxysmal ‘attacks’ of shock-like pain with 
periods of complete relief between episodes and is primarily unilateral. 
People with TNP, however, experience a continuous background pain 
often described as pins and needles or as burning pain, but also 
experience overlying attacks in addition to the smoldering pain they 
experience at baseline. They may also not have any evidence of 
neurovascular compression on imaging and more commonly 
experience bilateral symptoms. Sensory deficits are also more likely to 
accompany TNP than TN.1 
 Currently, the standard of care for TNP is treatment with high 
dose antiepileptics (primarily carbamazepine and oxcarbazepine), 
tricyclic antidepressants (TCAs), and opiates.4 Long term high doses of 
these medications carry a heavy side effect profile including dizziness, 
drowsiness and GI upset.5 A prior study investigated neurovascular 
decompression as a non-pharmacologic treatment for TNP, as it is in 
classic TN, but found that not only was this ineffective, it worsened 
pain in 73% of patients.6  
Targeted therapies of the trigeminal nerve, namely within the 
Gasserian ganglion (GG), have been a topic of interest in the 
treatment of TNP since the 1970s. The GG, also known as the 
trigeminal ganglion and less often, the semilunar ganglion, lies 
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between where the trigeminal nerve exits the pons and where it splits 
into its 3 primary branches.7 Stimulation of this structure was initially 
accomplished using a craniotomy approach which carried with it a 
multitude of risks and complications.4,8 In the 1984, Meglio developed 
a percutaneous approach to GG stimulation which resulted in pain 
relief in 86% of participants, however electrode dislocation and 
refining the surgical approach were still issues4,8. Although technology 
and techniques have improved vastly since this time, there has been 
little published research focusing on just those with TNP, not TN, in 
recent years and the standard of care remains pharmacologic 
treatment.  
 This literature review aims to determine if recent research 
supports stimulation of the GG for refractory trigeminal neuropathic 
pain as an effective treatment to reduce pain.  
METHODS 
An exhaustive search of literature was performed using Clinical 
Key, MEDLINE-Ovid, and Web of Science. Keywords used included: 
trigeminal neuropathic pain, stimulation, and neuromodulation. 
Studies were required to include only patients with TNP who were 
refractory to standard pharmacologic treatment. Studies that included 
patients with diagnoses of TN were excluded. Additional inclusion 
criteria included: studies in the English language, human studies, and 
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studies published within the last 15 years. Articles were assessed for 
quality using the Grading of Recommendations, Assessment, 
Development, and Evaluation (GRADE).9   
RESULTS 
The literature search yielded 182 articles for review. After 
removing duplicates and screening for relevant articles using exclusion 
criteria, there were 2 qualifying studies remaining10,8, both of which 
were case studies (Figure 1). Both studies were deemed to be very low 
quality given the inherent nature of case studies (Table 1). Currently 
no randomized controlled trials exist on this specific topic. Both 
studies10,8 utilized the visual analogue scale (VAS) to evaluate pain 
severity pre and post intervention.  
Kustermans et. al 
 This study10 was a 24-month retrospective analysis of 22 
patients with TNP refractory to medication management. All underwent  
trigeminal nerve stimulation at the level of the GG between 2010-2015 
at a single center in Belgium. Etiologies of TNP varied; however, in 
82% of patients (18/22), the etiology was iatrogenic secondary to a 
surgical intervention.  Patient ages ranged from 32-76 with a mean 
age of 59. Sixteen patients were female. The mean VAS pain score 
prior to intervention was 9/10 (range 6-10).10  
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The authors conducted a 4-week trial of stimulation using a 
customized electrode and proceeded to permanent implantation for 
anyone who experienced subjective pain reduction during the trial. 
Seventeen (77.3%) patients met criteria based on subjective pain 
reduction (15 of whom experienced >50% reduction in pain) and 
received permanent implantation of the electrode. One of the original 
22 patients could not be evaluated for permanent implantation 
secondary to requesting and receiving euthanasia.10  
At 6 months, an additional patient failed to reach follow up 
secondary to suicide. Fifteen of the remaining 16 (93.8%) continued to 
experience pain reduction.10 
At 24 months, another patient failed to reach follow up 
secondary to suicide. Seven of the remaining 15 (46.7%) of patients 
continued to experience pain reduction. Two had completely ceased 
use of any pain medication. The authors found a positive predictive 
value of 44% for long-term pain relief following a positive trial 
period.10  
Several complications were noted in the 17 patients that 
underwent permanent implantation. Seven patients (41%) 
experienced some level of physical discomfort such as muscle 
cramping or neck fibrosis where the electrode met the lead. The 
authors propose that a longer electrode would allow for a more 
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advantageous surgical technique and reduce the incidence of this 
complication. Additionally, four patients (24%) experienced an intra-
oral erosion secondary to implantation.10  
Machado et. al 
 This study8 included 10 patients (5 male, 5 female) with TNP 
that had exhausted pharmacologic management. The etiology of TNP 
in this population was dental, traumatic, or surgical in nature and 
involved various combinations of involvement in all 3 branches of the 
fifth cranial nerve.  Median age of patients was 46 years (range 37-
65). Visual analogue scale (VAS) pain questionnaires (0-10) were 
completed at baseline and again post-implantation at 1 month, 6 
months, and 1 year.8  
An initial 7-10 day trial period of trigeminal nerve stimulation at 
the level of the GG was conducted using an external electrode 
(Medtronic). All patients were implanted using a similar surgical 
technique. Machado et. al defined a successful initial trial of 7-10 days 
as >50% pain reduction on the VAS pain scale. At the end of this trial, 
8 patients met criteria for a successful trial and went forward with 
permanent implantation. The baseline mean VAS score in the 8 
patients that proceeded to permanent implantation was 6.5/10. The 
mean VAS was not reported for the initial 10 included in the trial.8  
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At 6 months, 3 of the 8 patients were withdrawn from the study 
due to explantation secondary to loss of efficacy (2) and no follow-up 
(1). Of the 5 patients remaining, 3 still continued to experience >50% 
pain reduction (mean VAS score 3/10, range 3-3) at 12 months and 2 
no longer had significant change in pain score compared to baseline 
(mean VAS 7/10, range 7-7). Of the 3 that experienced continued pain 
relief, 2 were able to reduce opioid intake by 50% and 1 was able to 
completely cease opioid use. There were no post-procedural 
complications to report in this study.8 
DISCUSSION 
TNP can be a debilitating facial pain condition and frequently 
does not respond to the traditional treatment of high-dose epileptics. 
Surgical intervention is not widely used due to a lack of quality 
research. Pharmacologic options are quickly exhausted and carry a 
large profile of side effects at the doses needed to lessen pain to a 
manageable level.    
Given the nature of case studies, the quality of this research is 
poor. However, there does seem to be some promise in the little data 
available. Both studies10,8 demonstrated success in long-term pain 
reduction at 12-24 months at 46.7% and 30%, respectively. However, 
an even greater number experienced at least short-term pain relief at 
6 months: 93.8% and 62.5%, respectively. In the largest of these 
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studies10, 80% those that experienced a lack of efficacy in the 
electrode after initial success did so after six to 24 months. It is 
unclear what the patient perspective is on the risks versus benefits on 
even short term relief.  
Each study included patients with varying combinations of 
branch involvement resulting from multiple etiologies (traumatic, 
dental, post herpetic). Patients were from similar age groups with 
mean ages of 59 and 56, respectively, and all had previously 
attempted to achieve pain relief through pharmacologic management.  
 Each study required an initial trial, used a similar surgical 
technique for implantation aimed at the GG, and followed patients for 
a minimum of 1 year to measure pain reduction. Initial trial lengths to 
determine candidacy for long term implantation varied (1 week8 versus 
4 weeks10); however, both allowed for patient control of the frequency 
generator in the initial trial phase to determine an effective level for 
pain control. It is not reported in the study with a 4-week trial10 if the 
frequency selected by the patient was any different at the end of the 
first week and the end of the fourth week, and this could be valuable 
knowledge to help determine an appropriate future trial length.  
Some variance existed amongst trials regarding the qualifying 
criteria to move a patient forward from a trial to a permanent implant. 
Machado et al study8 defined a successful trial as >50% reduction in 
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pain whereas Kustermans et al10 counted success as any subjective 
relief in pain. However, in the Kustermans et al study,10 88% of 
patients experienced >50% pain reduction in the initial trial. 
Unfortunately, Kustermans et al10 did not provide data on if those that 
experienced less than 50% pain relief initially were a part of the group 
that eventually experienced long-term pain relief. At this time, it is 
unclear whether >50% pain reduction is a predictor for long-term 
success. Moreover, each study utilized a different electrode which 
could account for variances in success rates.   
Kustermans et al10 was the largest of the 2 studies with 22 
enrolled however this is still considered a small sample size. Moreover, 
16 of these patients were female, making this demographic 
unbalanced. Perhaps the greatest flaw in this trial is that the 3 patients 
(13.6%) that ended their lives during the trial were not accounted for 
in the calculation of trial success rates. It is unclear if suicide, and in 1 
case euthanasia, were related to an unsuccessful trial due to 
inadequate pain relief or related to other issues. This information 
would be critical to include in these calculations. Instead, they were 
reported as “lost to follow up” and removed from success rate 
calculations.10   
Another concern of the Kustermans et al trial10 is the use of a 
custom made lead which can make reproducibility an issue for future 
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trials. This lead was made in partnership with a larger manufacturer, 
Medtronic, but it is unclear if it would be available for future research. 
The authors did hypothesize that a longer electrode would reduce the 
complications experienced in the trial, but this has not been 
investigated.10  
The loss of 3 patients to either suicide or euthanasia in the 
Kustermans et al trial10 cannot be overemphasized as it speaks to the 
burden of this condition. In this trial10, nearly 2/3 of patients had a 
history of or currently met criteria for a major mood or anxiety 
disorder. Although there are currently no estimates on the number of 
people who take their lives secondary to poorly managed TNP, the 
cyclical relationship between chronic pain and depression has been 
well established.3 Psychological evaluation should be a critical part of 
assessing and treating these patients.  
The Machado et al study8 was limited by extremely small sample 
size and technical complications. However, the subject population was 
homogenous and follow-up was adequate. The authors hypothesize 
that electrode migration could have affected outcomes for long-term 
efficacy and that their anchoring technique could be improved.8  
There is a clear lack of quality research on trigeminal nerve 
stimulation for refractory TNP. Of the studies that do exist, most 
include patients with TN and do not exclusively look at those with TNP. 
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Currently no RCTs exist, but the plausibility of conducting a study like 
this is uncertain. Without larger and higher quality research on this 
intervention, it is less likely to be considered as a treatment option. 
Additionally, further research could help to identify ideal candidates 
and trial length as well as to evaluate safety.  
 
CONCLUSION 
GG stimulation for TNP is minimally invasive and has not been 
shown to have significant morbidity nor any mortality associated with 
this intervention. However, no specific safety studies exist and should 
be explored alongside lead design and implantation techniques.  
Although the majority of patients in these studies did not 
experience long term pain relief, given the high level of suffering with 
this condition it could be considered as a treatment option when 
pharmacologic management has failed. Moreover, this intervention 
could be considered early in treatment given the psychological impact 
of chronic pain. Expectation management with the patient is crucial. 
Neither study evaluated whether patients that experienced even short 
term pain relief, or those that experienced a complication, still found 
the intervention beneficial.  
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Table 1: Quality Assessment of Reviewed Articles 
Study Design 
Downgrade Criteria 
Upgrade 
Criteria 
Quality 
Limitations Indirectness Inconsistency Imprecision 
Publication 
bias 
Kustermans 
et al10 
Case series, 
retrospective 
Very 
Seriousa 
Seriousb   Not serious Very 
Seriousc,d 
Not likely  None Very 
Low 
Machado et 
al8 
Case series, 
prospective 
Very 
Seriousa 
Not serious Not serious Seriousc Not likely None Very 
Low 
a No control group  
b  16/22 patients were female 
c Small sample size 
d High attrition rate  
